Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2022 Jun 13:10.1111/all.15395. Online ahead of print. doi: 10.1111/all.15395

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

(A, B) Decrease in Delta (δ)‐neutralizing antibody (NA) titers after double vaccination followed by mRNA booster‐induced increase. Geometric mean titers (GMT) and prevalence of titers >1:10 are tabulated. (C) Renewed titer decline. Increase of δ‐NAs four weeks after second (homologous/heterologous) and third mRNA dose (vertical dotted lines; p = 0.04; Mann–Whitney). (D, E) Increase in CD4+ and CD4/CD8+ T‐cell reactivity after mRNA booster. (F) Renewed decrease in T‐cell reactivity. Indicated are the number of individuals (N)/samples (S) tested, and cut‐off values (co). ****p < 0.0001; ***p < 0.001; **p < 0.01; ns: not significant (Kruskal—Wallis)